Improvement in lipid and haemostasis patterns after Helicobacter pylori infection eradication in type 1 diabetic patients.
Helicobacter pylori has been implicated in the cardiovascular risk of diabetic patients. The aim of our study was to investigate whether the Helicobacter pylori infection plays a role in the lipid and haemostasis patterns of type 1 diabetic patients. Twenty nine patients with type 1 diabetes mellitus and H. pylori infection were enrolled (Chlamydia pneumoniae negative). The H. pylori infection status was assessed by serology and urease breath test. In all patients levels of total cholesterol, triglyceride, HDL cholesterol, LDL cholesterol, lipoprotein (a) (Lpa) C reactive protein (CRP), fibrinogen, thrombin/antithrombin III complex (TAT), plasminogen activator inhibitor type 1(PAI-1), tissue plasminogen activator (t-PA) and von Willebrand antigen were measured. All patients were evaluated before and after H. pylori eradicating treatment with amoxicillin, clarithromycin and omeprazole. Twenty two patients were eradicated and seven remained infected. In H. pylori eradicated patients, HDL cholesterol increased (59.7+/-18.9 mg/dl vs 65.2+/-15. 9 mg/dl, P << 0.05), after treatment. After H. pylori eradication, the levels of CRP and TAT decreased (48+/-0.7 ng/l vs 3.3+/-0.4 ng/l;P << 0.05), (27.7+/-44.7 microg/ml vs 2.1+/-1.4 microg/ml, P << 0.05), respectively. The decrease in TAT was higher in the group of H. pylori (+) patients with higher levels of TAT (TAT >> 20 ng/ml, 92.8+/-41.6 ng/ml vs 1.9+/-2.0 ng/ml, P << 0.005; TAT 4Eth 20 ng/ml; 10.1+/-5.2 ng/ml vs 2.2+/-0.6 ng/ml, P << 0.05). These changes did not occur in patients without H. pylori eradication. Eradication of H. pylori infection in type 1 diabetic patients modifies some parameters of lipid and haemostasis patterns, (increase of HDL-cholesterol, reduction of Lpa and decrease of CRP and TAT) and so contributes to improvement of cardiovascular risk factors in these patients.
de Luis
D A
DA
Department of Endocrinology, Hospital Ramon y Cajal, Universidad de Alcala de Henares, Madrid, 28034, Spain.
Garcia Avello
A
A
Lasuncion
M A
MA
Aller
R
R
Martin de Argila
C
C
Boixeda de Miquel
D
D
de la Calle
H
H
D000328:Adult; D000658:Amoxicillin / Q000627:therapeutic use; D000704:Analysis of Variance; D015992:Body Mass Index; D001944:Breath Tests; D002784:Cholesterol / Q000097:blood; D017291:Clarithromycin / Q000627:therapeutic use; D003922:Diabetes Mellitus, Type 1 / Q000097:blood* / Q000150:complications / Q000378:metabolism; D004359:Drug Therapy, Combination / Q000627:therapeutic use*; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D016481:Helicobacter Infections / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism; D016480:Helicobacter pylori; D006487:Hemostasis; D006801:Humans; D008055:Lipids / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000627:therapeutic use; D010959:Tissue Plasminogen Activator / Q000097:blood
D000658:Amoxicillin; D002784:Cholesterol; D017291:Clarithromycin; D006442:Glycated Hemoglobin; D008055:Lipids; D009853:Omeprazole; D010959:Tissue Plasminogen Activator